🔴 Tscan Therapeutics is trading 10.5% down with no clear catalyst identified

Tscan Therapeutics is trading 10.5% lower at $0.26, with no clear company-specific catalyst identified.

• No new company-specific announcement or clear catalyst was identified for October 6, 2026; the investor-relations release page lists its latest press release as June 3, while recent company disclosures predate this session.
• Biotech-sector weakness offered context: XBI was down about 2.9% intraday, but this does not establish the full cause of the larger stock move.
• Major indexes were higher, so there is no clear broad-market explanation.